ArticleHereditas2026
Recognition and confirmation of key genes associated with nicotinamide metabolism in acute myocardial infarction.
Article in Hereditas, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe role of nicotinamide in improving cardiac function suggests its therapeutic benefit for acute myocardial infarction (AMI). This study aims to identify key genes associated with nicotinamide metabolism in AMI, offering novel insights into its therapeutic management.
methodsThe GSE60993 and GSE61144 datasets were retrieved from the database. Mendelian randomization (MR) analysis, Cytoscape-plugin cytoHubba algorithms, and expression validation were used to identify key genes linked to nicotinamide metabolism. Subcellular localization, gene set enrichment analysis (GSEA), immune infiltration analysis, drug prediction, and molecular docking were then performed. Finally, the expression of key genes was validated experimentally in clinical samples.
resultsThree key genes (FLT3LG, ITGB7, and PARP1) were found to be causally associated with AMI, ranking in the top three of the three Cytoscape-plugin cytoHubba algorithms. FLT3LG and ITGB7 were identified as risk factors (odds ratio [OR] > 1, P-value < 0.05), while PARP1 was a protective factor (OR < 1, P-value < 0.05). Expression analysis in GSE60993 and GSE61144 confirmed similar trends for these genes. FLT3LG and ITGB7 were predominantly located in the cytoplasm, whereas PARP1 was mainly in the nucleus. GSEA results indicated involvement of these genes in pathways such as the ribosome, oxidative phosphorylation, and spliceosome. Immune infiltration analysis showed that neutrophil scores were higher in AMI and negatively correlated with ITGB7 (cor = -0.84), PARP1 (cor = -0.75), and FLT3LG (cor = -0.86). Drug prediction and molecular docking revealed strong correlations between the key genes and Tetradioxin, with excellent binding ability. Expression trends of the three genes in clinical samples aligned with bioinformatics findings.
conclusionsThis study identified three genes associated with nicotinamide metabolism whose altered expression or function may have played a role in the pathological process of AMI. These genes could provide potential reference points for the diagnosis and treatment of AMI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.